A once‑daily oral medication that tackles type 2 diabetes while supporting weight reduction has entered pharmacies across the United Kingdom, marking the first European launch of a tablet‑based GLP‑1 therapy. Marketed under the brand name Foundayo and developed by US pharmaceutical giant Eli Lilly, the drug – known internationally as Orforglipron – is now dispensed only on a private prescription, with health‑service rollout still under review.
A New Oral Therapy Hits the Market
The tablet, taken at any time of day without the need for food or water, has received regulatory clearance from the Medicines and Healthcare products Regulatory Agency (MHRA) earlier this month. It is indicated for adults with a body‑mass index (BMI) of 30 kg/m² or higher, or for those with a BMI between 27 kg/m² and 30 kg/m² who also suffer from at least one weight‑related condition such as hypertension or dyslipidaemia. In addition, the product can be prescribed to improve glycaemic control in patients whose type 2 diabetes is inadequately managed with existing regimens.
Clinical data presented by Eli Lilly suggest that the medication delivers a modest but statistically significant reduction in average body weight after 12 weeks of treatment, while simultaneously lowering fasting glucose levels. The once‑daily dosing schedule is designed to improve adherence compared with injectable GLP‑1 analogues, which require scheduled subcutaneous administration.
“The UK is the first country in Europe where Foundayo is now available,” said Khalil Asmar, vice‑president of cardiometabolic health at Lilly Northern Europe. “We’re pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments.”
Regulatory Green Light and NHS Prospects
Following the MHRA’s approval, Eli Lilly has indicated that the drug will initially be accessible only through private prescriptions, pending a separate assessment by the National Institute for Health and Care Excellence (Nice). The company is collaborating with Nice to evaluate the therapy’s cost‑effectiveness and clinical value for potential inclusion on the NHS in England.
The licensing framework mirrors that of the first oral GLP‑1 tablet for weight management, which received UK clearance in June 2026. That earlier approval set a precedent for tablet‑based GLP‑1 agents, but Foundayo distinguishes itself by targeting both oestrogenic appetite pathways and glucose homeostasis in a single daily dose.
Health‑care analysts anticipate that the private‑prescription model will allow a subset of patients – particularly those who cannot tolerate or prefer to avoid injectable therapies – to obtain the medication relatively quickly, while the NHS evaluation could take several months to finalise.
Counterfeit Threat Looms Over Pill Market
The rapid commercial introduction of a new oral GLP‑1 agent has inevitably attracted a shadow market of unlicensed and counterfeit products. Last year, the MHRA recovered approximately £250,000 worth of counterfeit weight‑loss pens and raw ingredients from a manufacturing facility in Northampton. Eli Lilly has subsequently launched legal action against a network of suppliers it believes are distributing falsified versions of its injectable and tablet products.
Pharmacists have warned that the pill format is particularly vulnerable to counterfeiting because it can be produced in smaller batches without the stringent cold‑chain requirements associated with injectables. “There must now be a redoubling of efforts within government and the NHS to use pharmacies to make sure more eligible patients in clinical need can get weight loss treatments on the NHS, rather than the current postcode lottery that exists for weight management services via GPs,” said Henry Gregg, chief executive of the National Pharmacy Association.
Patients are being urged to source their medication exclusively from regulated pharmacies that can verify authenticity and storage conditions. The MHRA has reiterated its commitment to cracking down on illicit suppliers, but industry bodies stress that vigilance must be continuous as the market expands.
Industry and NHS Press for Expanded Access
The debut of Foundayo coincides with a broader push from professional organisations to embed weight‑management therapies within the public health system. Gregg highlighted that the availability of a second oral weight‑loss option “is particularly significant for patients who cannot or do not want to take an injectable medicine and could make weight‑loss treatment available to a wider range of patients.”
He called for a coordinated strategy to ensure that private‑prescription pathways do not become a permanent parallel system, but rather a stepping stone toward universal NHS provision. “The current postcode lottery that exists for weight management services via GPs must be addressed,” he added, emphasizing the inequities that can arise when access depends on geographic location rather than clinical need.
The convergence of regulatory approval, commercial rollout, and public‑health advocacy underscores a pivotal moment for oral GLP‑1 therapies in the UK, with stakeholders awaiting Nice’s final recommendation that could determine whether Foundayo becomes a routine part of the National Health Service’s arsenal against obesity and type 2 diabetes.
Why it Matters
The introduction of Foundayo represents a watershed in how Britain tackles two intertwined health crises – type 2 diabetes and obesity – by offering a convenient, oral alternative to injectable GLP‑1 drugs. Its private‑prescription launch immediately expands choice for patients who have been excluded from NHS weight‑management pathways due to access barriers or personal preference. Yet the accompanying surge in counterfeit products underscores a fragile regulatory landscape that could jeopardise patient safety if unchecked. The pressure on Nice and the NHS to fast‑track a full‑scale rollout reflects a growing consensus that weight‑loss medicine must move from a niche, privately funded option to a universally available component of preventive care. Failure to embed these therapies within the public system risks perpetuating the very disparities – postcode‑based access, delayed treatment, and reliance on black‑market substitutes – that the health service has pledged to eradicate. In short, the success of Foundayo will be a litmus test for the UK’s ability to translate scientific innovation into equitable, safe, and sustainable patient care.
